company background image
5XS2 logo

LexaGene Holdings DB:5XS2 Stock Report

Last Price

€0.084

Market Cap

€10.1m

7D

0%

1Y

-37.4%

Updated

21 May, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

5XS2 Stock Overview

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. More details

5XS2 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

LexaGene Holdings Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for LexaGene Holdings
Historical stock prices
Current Share PriceCA$0.084
52 Week HighCA$0.21
52 Week LowCA$0.041
Beta2.25
1 Month Change0%
3 Month Change0%
1 Year Change-37.37%
3 Year Change-84.62%
5 Year Change-89.60%
Change since IPO-50.41%

Recent News & Updates

Recent updates

Shareholder Returns

5XS2DE Medical EquipmentDE Market
7D0%-0.5%-0.3%
1Y-37.4%-8.4%7.0%

Return vs Industry: 5XS2 underperformed the German Medical Equipment industry which returned -2.5% over the past year.

Return vs Market: 5XS2 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 5XS2's price volatile compared to industry and market?
5XS2 volatility
5XS2 Average Weekly Movementn/a
Medical Equipment Industry Average Movement6.6%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 5XS2's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 5XS2's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200733Jack Reganwww.lexagene.com

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets; and assay panels. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection.

LexaGene Holdings Inc. Fundamentals Summary

How do LexaGene Holdings's earnings and revenue compare to its market cap?
5XS2 fundamental statistics
Market cap€10.13m
Earnings (TTM)-€7.90m
Revenue (TTM)€96.51k

104.9x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
5XS2 income statement (TTM)
RevenueUS$104.27k
Cost of RevenueUS$757.46k
Gross Profit-US$653.19k
Other ExpensesUS$7.89m
Earnings-US$8.54m

Last Reported Earnings

Nov 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.061
Gross Margin-626.46%
Net Profit Margin-8,189.91%
Debt/Equity Ratio66.4%

How did 5XS2 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/21 18:32
End of Day Share Price 2023/02/21 00:00
Earnings2022/11/30
Annual Earnings2022/02/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LexaGene Holdings Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sally YanchusBrookline Capital Markets
Neil LinsdelliA Capital Markets
Chelsea StellickiA Capital Markets